Background. The arterial pharmacokinetics of ketamine and norketamine enantiomers after racemic ketamine or S-ketamine i.v. administration were evaluated in seven gelding ponies in a crossover study (2-month interval).
important and highlights the need for stereospecific drug assays. 6 In humans and mice, the S-enantiomer has been proven advantageous, reaching an identical depth of anaesthesia with only half of the necessary racemic dose. [7] [8] [9] Differences in the metabolism of the ketamine enantio mers after R-/S-ketamine administration when compared with the sole S-ketamine administration might partially explain the faster recovery of the psychomotor function observed when S-ketamine is given alone.912
As a prelude to studying ketamine infusions in horses, the main goal of this study was to determine the pharma cokinetic profile of ketamine enantiomers after a single i.v. bolus of either R-/S-ketamine or S-ketamine in healthy ponies under isoflurane anaesthesia.
Materials and methods

Study design and animals
The experiments were performed with permission of the committee for animal experimentation, Bern, Switzerland. The experimental trial was designed as a randomized pro spective 2-month interval cross-over study. Seven exper imental, 4 year-old, Shetland pony geldings, mean weight 122 kg (sd 16 kg), were included in this study. The ponies were administered first R-/S-ketamine (RS-k) and after 2 months of wash-out interval, S-ketamine (S-k). They were conventionally housed as a group at the equine clinic of the Vetsuisse-Faculty (Bern, Switzerland). The animals had their right carotid artery surgically elevated to allow easy access by percutaneous puncture about 2 yr before this experiment and were judged healthy on the basis of physical examination, complete blood count and biochem istry profile. On the day before the experiment, ponies were housed in a separate box to allow withholding of food for 24 h. Access to water was granted until 1 h prior to the study.
Anaesthesia and instrumentation
The whole animal experimental phase was conducted in a padded recovery stall to both induce anaesthesia and allow for a safe anaesthetic recovery. A broad rope to restrain horses was placed around the ponies' pectoralis region, then passed around their hind quarters below their quadriceps and anchored to itself over the left side of their chest. After protective bandaging of the extremities, an additional rope was placed around every metacarpus/ metatarsus. By pulling and stretching the ropes gently, the ponies were smoothly placed in right lateral recumbency and restrained in that position until anaesthesia induction was achieved. Ponies were trained to be restrained with this technique from prior studies. 13 Anaesthesia was then induced with isoflurane in oxygen (O2) via a hermetically closed face mask connected to a small-animal anaesthesia circle system (Roche Electronic Respirator 3100, F. Hoffmann-La Roche, Basel, Switzerland). The vapori zer was first set to 1% and isoflurane delivery started via the face mask (O2 flow: 6 litres min-1) and gradual incre ments of 0.5% were made over 5 min until the ponies reached an appropriate anaesthetic plane for endotracheal intubation (muscle relaxation, eyeball rotation, reduced pal pebral reflex, absence of swallowing reflex). Subsequently, a 14 mm ID cuffed rubber-silicone tube was placed into their tracheas and connected to the breathing system. Ponies were let to breathe spontaneously throughout the whole procedure. In the event of apnoea longer than 30 s, intermittent positive pressure ventilation (IPPV) was applied by manually squeezing the reservoir bag of the breathing system twice per minute until spontaneous venti lation was restored. Anaesthesia was maintained with iso flurane in O2 throughout the whole experiment, at each pony's predetermined individual minimum alveolar con centration (iMAC). The iMAC for each pony [mean 0.97% (sd 0.17%)] was determined in a previous study. 13 The skin over the right jugular vein and the left carotid artery was clipped and surgically prepared for percutaneous placement of intravascular catheters. The right jugular vein was catheterized with a 13-gauge catheter (Intranule PP, Vygon, Ecouen, France), and Ringer's lactate solution 10 ml kg-1 h-1 (RLS, Laboratorium Bichsel Baar, Switzerland) was delivered intravenously throughout the procedure with the aid of two volumetric infusion pumps (Vet/IV 2.2 Heska, Ballerup, Denmark). The left carotid artery was catheterized using a 20G/1.10x45 mm arterial catheter (B-D Arterial Cannula with FloSwitch, Ohmeda, Swindon, UK). Later on, the jugular port served for test drug administration and the arterial port served for blood sampling and invasive blood pressure monitoring. To facili tate test drug administration or blood collection, three-way stopcock valves were attached to the hubs of the venous and arterial catheters between the RLS line and the invasive blood pressure line, respectively.
Anaesthesia monitoring and physiological data collection
A lead II electrocardiogram was displayed and haemo globin oxygen saturation (Spo) was determined with a pulse oximeter infrared probe placed on the tongue, which also calculated the pulse rate (PR). Inspired and expired O2 concentrations, end-expired isoflurane concentrations (Fe'jso). capnogram and end-tidal carbon dioxide partial pressure (Pi/o), tidal volume (VT), and minute volume ventilation (VE) were obtained from a calibrated pitot tube flow sensor and side-stream gas sampler probe (D-lite Patient Spirometry TM, Datex-Ohmeda, Helsinki, Finland) inserted between the endotracheal tube and the Y-piece of the breathing system. Respiratory rate (Ry) was calculated from the capnogram. Mean arterial pressure (MAP) was determined directly with a calibrated pressure transducer (Angiokard, Medizintechnik GmbH & Co. KG, Friedeburg, Germany) from the catheter placed in the carotid artery. The zero level in the transducer was set at the presumed level of the heart base (point of shoulder). In addition, the difference of the pharyngeo-oesophageal temperature (87' ) between the initial value measured after endotracheal intubation and the final value measured at the end of the procedures was recorded. A portable anaesthesia monitor (Datex S-5 portable anaesthesia monitor, Datex-Ohmeda, Helsinki, Finland) continuously displayed the aforemen tioned data. The monitor was calibrated with a stan dardized calibration gas (DOT-34 NRC/375M1014, Datex-Ohmeda, Helsinki, Finland) prior to each exper iment according to the manufacturers' instructions. A laptop computer connected to the monitor served to record every 5 min the displayed data from 5 min before the test drug administration (baseline data) and throughout the sampling time. In addition, the need for IPPV was also manually recorded. After complete recovery from anaes thesia, animals were returned to their boxes.
Drug administration and sample collection
Ponies were left to stabilize end-tidal isoflurane concen trations to their individual isoflurane MAC for about 20 min. A single i.v. dose of R-/S-ketamine (RS-k) 2.2 mg kg-1 or S-ketamine (S-k) 1.1 mg kg-1 were admi nistered intravenously. Five millilitres of arterial blood were collected manually over 5 s into heparinized tubes from the carotid artery catheter immediately before and at 1, 2, 4, 8, 16, 32, 64, 128 min after test drug injection. To avoid contamination with the arterial flushing solution, 5 ml of blood was collected and discharged before every sampling event. After the samples were obtained, the arterial catheter was flushed with 10 ml of physiologic saline solution. Immediately after collection, the samples were placed on ice until centrifugation was performed (maximum: 45 min) and plasma was frozen at -80cC until the assay was performed.
Ketamine and norketamine enantiomer analysis
The plasma samples were analysed by enantioselective capillary electrophoresis (CE) according to the technique described by Theurillat and colleagues,14 and plasma con centrations for R-ketamine, S-ketamine, R-norketamine, and S-norketamine were obtained. Briefly, this technique is based on liquid-liquid extraction of ketamine and nor ketamine at alkaline pH from 1 ml plasma followed by analysis of the reconstituted extract by CE in the presence of a pH 2.5 Tris-phosphate buffer containing highly sul fated p-cyclodextrin 10 mg ml-1 (Sigma Aldrich Chemie, Schnelldorf, Germany) as chiral selector. Analyses were performed on the P/ACE MDQ Capillary Electrophoresis Analyzer (Beckman Coulter, Fullerton, CA, USA) using a 50 p,m ID fused-silica capillary of 28 cm effective length, an applied voltage of 20 kV and a cartridge temperature of 30cC. The detection wavelength was 195 nm. The limit of detection for all enantiomers was 0.01p,gml_1 and intraday and interday precisions (n=5) were <8% and <14%, respectively.
Ph a rmcicoki neti c ana lysis
R-ketamine and S-ketamine concentration vs time curves were analysed for each individual by non-linear least square regression two-compartment model analysis using PCNonlin (SCI Software, Lexington, USA). Plasma con centration obtained after i.v. administration was fitted to a polyexponential equation:
where C(f) (jig ml-1) is the plasma concentration at time /; T, (jig ml-1) is the coefficient of the zth term, and X., (per hour) is its exponent. Initial estimates were determined using the residual method15 and refitted by non-linear regression analysis. The number of exponents needed were determined by applying the Schwartz16 and Akaike cri teria.17 Most pharmacokinetic parameters were calculated using classic equations associated with compartmental analysis. Distribution and elimination half-lives (i^alpha and ij^beta, respectively) were calculated as L/2 alpha=0.693/X.1 and /1/2beta=0.693/X,2-Area under the plasma concentration-time curve (AUC(o-M)) and mean residence time (MRT, measure of drug elimination expressed as the average time a drug molecule remains in the body after i.v. injection) were calculated by the trape zoidal rule with extrapolation to infinity. The extrapolated area was estimated as AUC(c co)=Ciast/X.2-where Ciast is the last measured concentration. Body clearance (C1B) was determined as ClB=dose/AUC(o-K>) and the steady-state volume of distribution (Vjdiss))) was calculated as V(d(ss))=ClBxMRT. Plasma disposition curves for R-norketamine and S-norketamine were described by esti mating AUC, Cmax, and Tmax.
Statistical methods
The NCSS 2004 (Kaysville, UT, USA) and the SigmaStat 3.1 (Point Richmond, CA, USA) software packages were used to perform the statistical evaluation. All data were analysed for normal distribution with the Martinez-Iglewicz test. The significance of difference between groups for 87', ketamine, and norketamine enantiomers plasma levels and the estimated pharmacokinetic parameters was assessed with the Wilcoxon signed rank test or, when applicable, the Student's paired /-test. Each animal served as its own match. For PR, MAP, F'e' co,, Rf. and VE, a statistical comparison was made between SR-k and S-k treatment groups before and after test drug administration using an analysis of variance test and for VT using a two-way analysis on ranks Friedman test. For all tests, overall P<0.05 was considered the minimum level of statistical significance. Parametric data are presented as mean (sd) and non-parametric data are presented as median and range.
Results
Anaesthesia
The overall induction, maintenance, and recovery from the anaesthetic episodes were uneventful. In one pony, the administration of the S-ketamine and the RLS infusions were performed via a 16-gauge catheter placed in the right cephalic vein because of obstruction of the left jugular vein catheter. Differences between treatment groups in 87' were not statistically significant [RS-k: 0.6 (0.4)cC; S-k: 0.9 (0.6)°C],
Cardiopulmonary data
There were no statistically significant differences in the cardiopulmonary variables between groups during the baseline measurements. Trends for PR are presented in Figure 1 . Ponies in the RS-k treatment group had signifi cantly lower (P<0.001) overall PR compared with the S-k treatment group (Fig. 1) . Trends for MAP are presented in Figure 2 . Overall MAP values where higher (P=0.006) in the RS-k when compared with the S-k group. Trends for Pe' co,, Ve-and Rf are presented in Figure 3 . Ponies in the S-k treatment group had a significantly lower (P<0.001) Pt.' co2 compared with the RS-k treatment group (Fig. 3a) . The VE was significantly higher (P<0.001) in the RS-k treatment group than in the S-k treatment group (Fig. 3b) . Overall Revalues were higher (P<0.001) in the RS-k treat ment group than the S-k treatment group (Fig. 3c) . Immediately after both test drug administrations, three of seven ponies in each group developed apnoea longer than 30 s. After applying IPPV for 1-2 min all of them restored to spontaneous respiration. Differences in VT were not stat istically significant between treatment groups (RS-k group, median: 1.04 litre, range: 0.24-2.61 litre; S-k group, median: 0.99 litre, range: 0.05-3.06 litre). VT decreased in both groups after test drug administration and restored to baseline values at 10 min. Mean Spo, for the entire anaesthetic episode was 99 (0.9)% in the RS-k treatment group and 98.8 (0.4)% in the S-k treatment group. 
Plasma concentrations of ketamine and norkefamine enantiomers
A total of 126 plasma samples (RS-k=63, S-k=63) were analysed by CE and used for the concentration-time data evaluation. R-ketamine and R-norketamine were not detected after administration of S-ketamine. Trends for ketamine and norketamine plasma concentrations are pre sented in Figures 4 and 5 . S-ketamine plasma concen trations were statistically significantly lower (P=0.03) in the S-k treatment group than in the RS-k treatment group at 2 min (Figs 4a and 5a) . At the same time point, S-ketamine plasma concentrations were statistically signifi cantly lower (P=0.005) when compared with the R-ketamine plasma concentrations in the RS-k treatment group (Fig. 4a) . No other significant differences were determined. Plasma concentrations for S-norketamine were statistically significantly higher than plasma concentrations of R-norketamine in the RS-k group at 2 (P=0. Fig. 5a ).
Ph a rmacoki neti c ana lysis
The pharmacokinetics for all ketamine enantiomers could be well described with a two-compartment model. No sig nificant differences in the pharmacokinetic variables between and within treatment groups could be detected for the ketamine enantiomers. The AUC and Cmax of R-norketamine were found to be significantly smaller (P=0.002 and P=0.009, respectively) than those of S-norketamine in the RS-k treatment group. No other sig nificant differences could be determined. Table 1 summar izes the results of the population analysis for all compounds.
Discussion
In the present study, the pharmacokinetic parameters of R-and S-ketamine after single i.v. injection of the race mate or the single S-enantiomer in ponies under isoflurane anaesthesia, did not significantly differ. The statistically significant differences found for the S-ketamine plasma concentrations 2 min after administration of either R-/Sor S-ketamine had no significant impact on the calculated pharmacokinetic variables. However, the statistically sig nificant differences found in the plasma disposition of Sand R-norketamine after administration of the racemate, mirrored by their calculated pharmacokinetic parameters, suggest that in ponies anaesthetized with 1 iMAC isoflur ane, the metabolism of racemic ketamine is highly stereoselective. In both treatment groups, the arterial plasma concentrations of ketamine enantiomers followed a biexponential decline, with a rapid initial distribution phase being followed by a slower elimination phase. This profile was analogous to those previously published for humans,11 dogs,18 and cross-bred horses.5 Similar to humans and most other species,1 2 15 111 18 21 high variabi lity among individuals was observed in the plasma con centrations of ketamine and norketamine. Former studies on the pharmacokinetics of S-/R-ketamine in horses reported data analysed from venous samples.15 In isoflurane anaes thetized ponies, large differences (up to 50%) were found between arterial and venous pharmacokinetics of ketamine isomers caused by both, distribution and elimination pro cesses.22 In situations in which potent short-acting drugs are used, such as anaesthetics, these differences can be of con siderable importance.23 Because the drug concentrations at the target organ are probably more closely related to arterial than to venous concentration, the controlling parameters should be based on arterial rather than venous data.10 24 The present study is the first investigating the arterial stereoselective pharmacokinetic profile of S-/R-ketamine compared with S-ketamine in an equine species. The iMAC is the midpoint of two end-tidal anaesthetic concentrations that just permit or just prevent gross purpose ful movement after applying a supramaximal stimulation in a single anaesthetized individual.25 Individual MAC values are normally averaged to obtain the MAC in a group of subjects. The use of each pony iMAC, instead of the MAC of the group, aimed to have a comparable degree of immobility among test animals. I.V. R-/S-ketamine at a dose of 2.2 mg kg-1 is well documented to induce anaes thesia in sedated horses.2 4 Such doses, however, are seldom administered in clinical practice to horses already receiv ing 1 MAC of isoflurane. This dose was chosen delibera tely to create a basis for further studies on constant rate infusion of ketamine in isoflurane-anaesthetized horses. As a racemate has equal proportions of each enantiomer, a dose of 1.1 mg kg-1 of S-ketamine was chosen to compare the profiles of the S-enantiomer in both treatment groups.
Previous investigations in rats21 and dogs26 anaesthe tized with halogenated agents showed alterations in organ perfusion, which in turn slowed down uptake, distribution, and redistribution of ketamine. Thus, an increased appar ent volume of the central compartment (Vc) could be expected, probably because of a slower elimination of the compounds by poorly perfused organs of elimination. It has long been suggested that distribution of drugs may be not only affected by blood flow but also by active transport across the endothelium.27 It was postulated that the binding affinity of the chiral forms of ketamine to mem brane receptors responsible for protein-mediated transport across the vascular endothelium might exhibit stereospeci ficity, showing different distribution profiles between enan tiomers. However, several authors failed to demonstrate ketamine distribution to be stereoselective in humans10 11 28 and in dogs.18 Similarly, in the present study, the half-lives and the Vc for the ketamine enantiomers did not differ significantly between and within groups, suggesting that ketamine distribution is not enantio selective in the equine species either.
MRT and C1B values calculated from the arterial plasma ketamine concentrations determined after S-ketamine or R-/S-ketamine i.v. administration were similar for all enantiomers. Studies conducted in humans showed a significantly higher C1B for S-ketamine compared with R-ketamine after administration of either enantiomer. " " Ihmsen and colleagues10 showed a higher S-ketamine body clearance in men when the drug was administered as an infusion of the pure enantiomer compared with an infusion of the racemate. In contrast, Yanagihara and colleagues30 showed no differences between the pharmacokinetics of ketamine enantiomers and this dissimilarity was attributed to variability related to human races. Inter-individual variations between comparison groups, differences in the sampling site (arterial vs venous), or both might also account for such discrepancies. 10 Several factors seem to have an important impact on the metabolism of the ketamine isoforms. Ketamine is rapidly and extensively metabolized by the hepatic microsomal cytochrome P450 enzymes to norketamine, hydroxynorke tamine, hydroxyketamine, and dehydronorketamine. 31 35 In vitro studies revealed that A'-dcrncthylation of S-ketamine by human liver microsomes is 20% larger than that of R-ketamine and 10% greater when compared with the racemic compound.36 Two enzymes with stereospecific preference for one enantiomer over the other, or four enzymes with different stereospecific substrate activities and different metabolic rates might account for this enantioselective A'-dcrncthylation. 36 In contrast another in vitro study with human liver microsomes suggested a non-enantioselective A'-dcrncthylation of R-and S-ketamine. 37 The comparable values obtained for the calculated phar macokinetic variables of the S-isoforms of ketamine and norketamine in both groups suggest no interference of the R-enantiomer with the overall elimination of the S-enantiomer in the racemate. However, the significant differences found for the R-and S-norketamine in the RS-k treatment group suggest that some differences exist with regard to their particular metabolic pathways. This finding corresponds with data in which similar results were obtained after a single dose of S-or R-/S-ketamine administration to human patients11 and horses.5 In the latter study, a S/R ratio for norketamine of 75:25 immedi ately after and 90:10 40 min after i.v. administration of R-/S-ketamine (6 mg kg-1) was reported. The authors postulated that these ratios could be the consequence of substrate enantioselectivity of the cytochrome-dependent A'-dcrncthylation. In the present study, an enzymesubstrate competition seems unlikely because similar C1B rates were found for the S-enantiomer in both groups suggesting the presence of other enantioselective processes involved in the elimination of ketamine. Norketamine is a pharmacologically active metabolite and was found to have a potency of around 30% of that of the parent drug. 38 The hydroxylated metabolite 6-hydroxynorketamine has been reported to be a weaker anaesthetic and to produce less post-anaesthetic excitation than norketamine.39 Consequently, norketamine elimination pathways might have a relevant influence on the overall ketamine activity. Interestingly, the hydroxylation of norketamine also exhibited enantioselectivity at different positions on the cyclohexanone ring.35 Therefore, it could be possible that in the present study, R-norketamine hydroxylation may have prevailed, accounting for the lower plasma concen trations reflected into the lower AUC and Cmax observed for that metabolite. Unfortunately, we were unable to quantify the plasma concentrations of the hydroxylated forms of norketamine to test this hypothesis.
Renal excretion seems to play a significant role in nor ketamine elimination in horses.40 Differences in plasma protein binding leading to different renal clearance may be expected for chiral compounds.41 Therefore, different renal clearance rates for norketamine enantiomers could also explain the higher concentrations obtained for S-norketamine in ponies' plasma when compared with those of R-norketamine. Kaka and colleagues4 proposed involvement of extrahepatic pathways in the ketamine metabolism in horses because the ketamine C1B exceeded the calculated hepatic plasma flow rate. Studies performed in rats reported extrahepatic inversion of R to S-ketamine with subsequent metabolism to S-norketamine. 42 In the present study, no R-ketamine was detected after adminis tration of the pure S-enantiomer, and after administration of the racemate, the mean plasma concentrations of R-and S-ketamine were similar, suggesting no inversion between the R-and S-enantiomers. Geisslinger and colleagues11 proposed that a possible inversion from R-to S-ketamine could be masked by different stereoselective C1B rates, resulting also in similar concentration profiles for both enantiomers. However, the C1B of the R-and S-ketamine were similar in our study.
Although the study reported here was mainly designed to evaluate the pharmacokinetics of ketamine and norketa mine enantiomers, some cardiopulmonary data were also collected. Generally, low doses of R-/S-ketamine are known to increase heart rate and MAP as a consequence of direct sympathetic stimulation. 43 The reduction in MAP observed for both compounds in the first 10 min after drug administration could have been the result of direct central nervous system depression in response to the high doses used here. S-ketamine seemed to have produced a stronger cardiac stimulation as evaluated by higher PR values observed for the S-k group compared with the RS-k group. In vitro studies showed an inhibition of the uptake of nor adrenaline at adrenergic neuronal endings by ketamine, which occurred pre-synaptically with both enantiomers but also post-synaptically with the S-isoform. 44 On the other hand, overall mean MAP values remained significantly lower over time in the S-k treatment group compared with the racemate. The reduced MAP values observed in the S-k treatment group could have induced an autonomic reflex response that increased the heart rate and vice versa for the RS-k treatment group. Contrary to these findings, Filzek and colleagues45 reported significantly lower heart rate and higher MAP values in horses anaesthetized with S-ketamine compared with those receiving R-/S-ketamine. In man, several studies compared R-/S-ketamine with S-ketamine and found equivalent cardiovascular stimula tion.104647 Immediately after test drug administration and for about 10 min, respiratory depression occurred (apnoea, decreases in Rf, VT, and VE). A progressive increase in VE was observed in both groups as test drugs were cleared from plasma. Increases in Rf might have accounted for the overall increases in the mean VE values observed in the RS-k treat ment group since VT remained similar between groups. In turn, an overall increase in the arterial partial pressure of carbon dioxide, reflected as an increase in the overall mean Pecq values in the RS-k treatment group, could have stimu lated the respiratory system via chemoreceptor activity result ing in the observed increases in VE and Rf. Alternatively, increases in physiologic dead space could explain the lower Pe' cq values observed in the S-k treatment group.
In conclusion, the disposition of racemic ketamine in ponies anaesthetized with 1 iMAC isoflurane is stereo selective, leading to higher plasma concentrations of S-norketamine. Several factors seem to influence the metabolism of the ketamine isoforms. Further studies are required to assess the impact of different dose regimes, drug combinations, or both on the overall metabolism of the enantiomers of ketamine. Under the conditions reported here, administration of S-ketamine produced different cardiopulmonary effects than those observed with R-/S-ketamine. The underlying mechanisms responsible for these differences remain to be elucidated. 
